Pharma Leaders

The Impact of FDA’s Guidance on Mammography Quality Standards Act: Q&A with Steven C. Quay

2 months ago
by David Miller
946 Views

Atossa Therapeutics’ CEO discusses how the new draft guidance will change the way that many women receive their breast exam results.

Atossa Therapeutics’ CEO discusses how the new draft guidance will change the way that many women receive their breast exam results.

You may also like

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

View all posts

Don`t Leave Yet!

Thank you!

[mwai_chat window="true" fullscreen="true"]